Find practical information about diabetes treatment and management, including blood sugar monitoring, medications, lifestyle changes, complications and everyday diabetes care.
A pooled analysis of large clinical trials suggests tirzepatide may enhance blood sugar control and reduce weight gain when added to basal insulin in adults with longstanding type 2 diabetes, offering new hope for intensifying treatment without additional hypoglycaemia risk.…
Abbott Laboratories has received FDA clearance for its new Libre Duo 10 Day wearable device, the first in the US to continuously monitor both glucose and ketone levels, potentially transforming diabetes management and risk detection. Abbott Laboratories has won US…
A recent mouse study presented at ENDO 2026 complicates the view that cutting sugar automatically improves metabolic health, highlighting the nuanced role of dietary carbohydrates in gut and immune function and warning against extreme restrictions. A new mouse study presented…
The US Food and Drug Administration has authorised the Libre Duo 10 Day system, a groundbreaking wearable that tracks glucose and ketone levels simultaneously, potentially transforming diabetic ketoacidosis prevention and management. The US Food and Drug Administration has authorised the…
As GLP-1 treatments like semaglutide and liraglutide reduce appetite and alter digestion, experts emphasise the importance of tracking diet, hydration and micronutrients to prevent deficiencies and support overall health. People taking GLP-1 medicines may find that eating less feels almost…
Despite a new Medicare pilot programme aimed at making GLP-1 weight-loss medications more affordable, restrictions based on health conditions leave out many patients, including a retired professor with severe obesity and health issues. Jeff La Marca thought he had found…
While clinical trials show significant weight regain after stopping GLP-1 medicines like semaglutide and tirzepatide, recent real-world research highlights the potential for sustained progress through follow-up care and lifestyle modifications, underscoring the importance of personalised long-term approaches. Research on GLP-1…
The US Food and Drug Administration has documented over 1,700 adverse-event reports related to illegal compounded versions of semaglutide and tirzepatide, amid rising regulatory scrutiny and ongoing market disputes in the lucrative obesity drug sector. The US Food and Drug…
With summer travel underway, Diabetes UK and footwear brand Gentle Grip warn that walking barefoot on hot sand or beaches can cause severe foot problems for diabetics, urging protective measures to prevent infections and amputations. People with diabetes are being…
Biomae Fusion has completed patient enrolment in its phase II trial of icovamenib, a potential breakthrough in insulin-deficient type 2 diabetes, with results now expected in early 2027, signalling a significant step forward for the experimental drug. Biomae Fusion said…
Eli Lilly’s Foundayo, the first approved once-daily GLP-1 tablet in Europe, is now available in UK pharmacies, offering a new oral treatment option for weight management and diabetes control, potentially expanding access for patients unable to use injectable medicines. A…
A small University of Illinois Chicago trial indicates that limiting eating to an eight-hour window may help some adults with type 1 diabetes improve blood glucose management safely, sparking cautious optimism for wider application. A small clinical trial from the…
